WO2018026249A1 - Antibody against programmed death-ligand 1 (pd-l1), and use thereof - Google Patents
Antibody against programmed death-ligand 1 (pd-l1), and use thereof Download PDFInfo
- Publication number
- WO2018026249A1 WO2018026249A1 PCT/KR2017/008495 KR2017008495W WO2018026249A1 WO 2018026249 A1 WO2018026249 A1 WO 2018026249A1 KR 2017008495 W KR2017008495 W KR 2017008495W WO 2018026249 A1 WO2018026249 A1 WO 2018026249A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- light chain
- variable region
- heavy chain
- chain variable
- Prior art date
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 129
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract description 129
- 239000000427 antigen Substances 0.000 claims abstract description 100
- 108091007433 antigens Proteins 0.000 claims abstract description 100
- 102000036639 antigens Human genes 0.000 claims abstract description 100
- 230000027455 binding Effects 0.000 claims abstract description 94
- 239000012634 fragment Substances 0.000 claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 78
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 abstract description 34
- 108090000623 proteins and genes Proteins 0.000 description 37
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 241000282414 Homo sapiens Species 0.000 description 31
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 239000000872 buffer Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000004091 panning Methods 0.000 description 14
- 239000003446 ligand Substances 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 7
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 7
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000002869 basic local alignment search tool Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 102000048776 human CD274 Human genes 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 102000048362 human PDCD1 Human genes 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 102000025171 antigen binding proteins Human genes 0.000 description 3
- 108091000831 antigen binding proteins Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101150027568 LC gene Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical group C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000593245 Bionia Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- -1 IFNα2 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention provides an antibody or antigen-binding fragment thereof for PD-L1 (Programmed death-ligand 1), a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, the antibody or an antigen-binding fragment thereof. It relates to a manufacturing method and a composition for preventing or treating cancer or infectious disease comprising the same.
- T-cell antigen receptors present on the surface of T-lymphocyte cells be the major histocompatibility complex (MHC) of antigen presenting cells (APCs). It begins by recognizing antigen bound to a human leucocyte antigen (HLA) Class II molecule, which requires co-stimulatory signals simultaneously with the recognition of the antigen in order for T-lymphocytes to be fully activated.
- HLA human leucocyte antigen
- CD80, CD40, and the like are combined with CD28, CD40L, etc., which correspond to ligands on the surface of T-lymphocytes, thereby activating the secretion of cytokines, and recognition of the antigen through the binding of TCR-MHC / epitopes. Even if there is no signal transmission of the simultaneous stimulus signal, the activity of T-lymphocytes is not achieved.
- activated T-lymphocytes also activate a co-inhibitory signal at the same time to become inactive after a certain time. This can prevent tissue damage due to excessive immune stimulation.
- CTLA-4 cytotoxic T lymphocyte antigen
- PD-1 programmed death-1
- -ligand 1 corresponding antigen-presenting cell ligands of T-lymphocytes.
- CTLA-4 has the inactivation function of naive or memory T-lymphocytes by binding to ligands CD80 and CD86, and PD-1 regulates T-lymphocyte function in peripheral tissues through PD-L1 and PD-L2. do.
- the body's immune function regulates T lymphocyte function through the regulation of co-stimulatory and co-inhibition signals as well as antigen recognition. This regulatory mechanism is called an immunocheckpoint.
- the immune function of our body detects tumor-specific neo-antigens expressed by mutations such as mutations occurring in tumor cells and thereby removes tumor cells or viral infectious agents.
- One such avoidance strategy is to inhibit the function of tumor specific T lymphocyte cells through alteration of immune checkpoint function. That is, by activating such inhibitory immunoassay in tumor cells, the attack of tumor specific T-lymphocyte cells is avoided.
- antitumor effects can be obtained by enhancing the tumor specific T-lymphocyte cell activity and effects inhibited by inhibiting its function using monoclonal antibodies against PD-1 or ligand PD-L1.
- the inventors of the present application tried to develop an antibody that specifically binds to PD-L1.
- the present inventors have developed an anti-PD-L1 antibody that binds PD-L1 with high affinity, and this anti-PD-L1 antibody inhibits the formation of the PD-1 / PD-L1 complex, resulting in the desired immunity.
- the present invention was confirmed that it can play a role of an anticancer agent or a therapeutic agent for infectious diseases.
- Another object of the present invention is to provide a nucleic acid encoding the antibody or antigen-binding fragment thereof.
- Another object of the present invention is to provide a vector comprising the nucleic acid, a cell transformed with the vector, and a method of manufacturing the same.
- Still another object of the present invention is to provide a composition for preventing or treating cancer or infectious disease comprising the antibody or antigen-binding fragment thereof.
- the present invention is a group consisting of heavy chain CDR1, SEQ ID NO: 8 to SEQ ID NO: 15 comprising a sequence having a sequence homology of 90% or more with a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:
- a heavy chain CDR2 comprising a sequence having at least 90% sequence homology with a sequence selected from among and a heavy chain CDR3 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 16 to 25
- a heavy chain variable region comprising a light chain and a light chain CDR1 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 88 to SEQ ID NO: 102, SEQ ID NO: 103 to SEQ ID NO: 119
- a light chain CDR2 comprising a sequence having 90% or more sequence homology with a sequence to be sequenced, and selected from the group consisting of SEQ ID NOs: 120
- the present invention also provides a nucleic acid encoding the antibody or antigen-binding fragment thereof.
- the present invention also provides a vector comprising the nucleic acid.
- the present invention also provides a cell transformed with the vector.
- the present invention also provides a method for producing the antibody or antigen-binding fragment thereof comprising the following steps: (a) culturing the cells; And (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.
- the present invention also provides a composition for preventing or treating cancer or infectious disease comprising the antibody or antigen-binding fragment thereof as an active ingredient.
- FIG. 1 is a schematic diagram of a PD-L1 expression vector.
- 2A is a 10% SDS-PAGE gel of PD-L1-hFc. Results of protein identification under RE (reducing) and NR (non-reducing) conditions;
- Figure 2b shows the G-3000 SWXL SEC-HPLC results. Flow rate is 1 ml / min and developing solvent is PBS;
- 2C is a 10% SDS-PAGE gel of PD-L1-mFc. Results of protein identification under RE (reducing) and NR (non-reducing) conditions;
- Figure 2d shows the G-3000 SWXL SEC-HPLC results.
- the flow rate is 1 ml / min and the developing solvent is PBS.
- Figure 3 shows the result of increasing the binding force for PD-L1 antigen according to the number of panning.
- Figure 4 shows the ELSIA results for measuring the binding capacity of monophages strong binding capacity only PD-L1-His.
- Figure 5 shows the result of confirming the selected PD-L1 antibody through SDS-PAGE.
- Figure 6 shows the results of in vitro efficacy evaluation of PD-L1 antibody.
- Figure 7 shows the results of the concentration-dependent in vitro efficacy evaluation of PD-L1 antibody.
- Figure 8 shows the results of measuring the binding force of the PD-L1 antibody in PD-L1 overexpressing cells.
- Figure 9 shows the results of the kinetic (kinetics) measurement between PD-L1-hFc and PD-L1-16E12.
- Figure 11 shows the results of evaluating the in vitro efficacy of the PD-L1 antibody according to the present invention.
- Figure 12 shows the results of evaluating the concentration-dependent in vitro efficacy of the PD-L1 antibody according to the present invention.
- Figure 13 shows the results of measuring the binding force of the antibody in PD-L1 overexpressing cells.
- Figure 14 shows the results confirming the inhibitory effect of the antibody preventing the formation of PD-1 / PD-L1 complex using enzyme immunosorbent in the selected antibody.
- FIG. 15 shows kinetic measurements of PD-L1-hFc and PD-L1-16E12-4F5.
- Figure 16 shows the binding measurement results of PD-L1 variant protein and monoclonal antibody.
- Figure 17 shows that the PD-L1 monoclonal antibody shows an increase in activity in heterologous MLR (Mixed Lymphocyte Reaction).
- Figure 19 shows the results confirming the binding of the anti-PD-L1 antibody according to the invention with PD-L2.
- the present invention is a heavy chain CDR1 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 7 selected from the group consisting of SEQ ID NO: 8 to SEQ ID NO: 15
- a heavy chain CDR2 comprising a sequence having at least 90% sequence homology with the sequence
- a heavy chain CDR3 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 16-25
- a light chain CDR1 comprising a heavy chain variable region and a sequence having 90% or more sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 88 to 102, and a sequence selected from the group consisting of SEQ ID NOs: 103 to 119; 90% or more of a light chain CDR2 comprising a sequence having at least 90% sequence homology, and a sequence selected from the group consisting of SEQ ID NOs: 120 to 144
- PD-L1 as used herein is a ligand for the immunosuppressive receptor “programmed death receptor 1 (PD-1)” that is primarily expressed on activated T and B cells, and PD-1 and ligand PD-L1 and / or Or when PD-L2 binds, negatively regulates antigen receptor signaling.
- Ligands for PD-1 may be constitutively expressed or induced into a number of cell types, including non-hematopoietic tissue and various tumor types.
- PD-L1 is expressed on B cells, T cells, bone marrow cells and dendritic cells (DCs), but also on peripheral cells, like microvascular endothelial cells and non-lymphoid organs such as heart, lung and the like.
- DCs dendritic cells
- PD-L2 is found only on macrophages and dendritic cells.
- the expression pattern of PD-1 ligand suggests the role of PD-1 in maintaining peripheral tolerance and may contribute to regulating auto-reactive T-cell and B-cell responses in the peripheral.
- Both ligands are type I mobile membrane receptors that contain both IgV- and IgC-like domains in the extracellular domain. Both ligands comprise short cytoplasmic regions with unknown signaling motifs.
- antibody refers to an anti-PD-L1 antibody that specifically binds to PD-L1.
- the scope of the present invention includes not only complete antibody forms that specifically bind PD-L1, but also antigen binding fragments of such antibody molecules.
- a complete antibody is a structure having two full length light chains and two full length heavy chains, each of which is linked by heavy and disulfide bonds.
- the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), and gamma 3 ( ⁇ 3). ), Gamma 4 ( ⁇ 4), alpha 1 ( ⁇ 1) and alpha 2 ( ⁇ 2).
- the constant regions of the light chains have kappa ( ⁇ ) and lambda ( ⁇ ) types.
- An antigen binding fragment or antibody fragment of an antibody means a fragment having an antigen binding function and includes Fab, F (ab '), F (ab') 2, Fv and the like.
- Fab in the antibody fragment has a structure having a variable region of the light and heavy chains, a constant region of the light chain and the first constant region (CH1) of the heavy chain has one antigen binding site.
- Fab ′ is a hinge region comprising one or more cysteine residues at the C-terminus of the heavy chain CH1 domain
- F (ab ') 2 antibodies are produced by disulfide bonds of cysteine residues in the hinge region of Fab'.
- Recombinant techniques for generating Fv fragments with minimal antibody fragments in which Fv has only heavy and light chain variable regions are described in PCT International Publication Nos. WO88 / 10649, WO88 / 106630, WO88 / 07085, WO88 / 07086 and WO88 / 09344. Is disclosed.
- Double-chain Fv is a non-covalent bond in which a heavy chain variable region and a light chain variable region are linked, and a single chain Fv (single-chain Fv, scFv) is generally a variable region of the heavy chain and the light chain through a peptide linker. This covalent linkage or the C-terminus is directly linked to form a dimer-like structure such as a double-chain Fv.
- Such antibody fragments can be obtained using proteolytic enzymes (e.g., restriction digestion of the entire antibody with papain yields Fab and cleavage with pepsin yields F (ab ') 2 fragments). It can also be produced by recombinant technology.
- the antibody according to the invention is in Fv form (eg scFv) or is in the form of a complete antibody.
- the heavy chain constant region may be selected from any one isotype of gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) or epsilon ( ⁇ ).
- the constant region is gamma 1 (IgG1), gamma 3 (IgG3) or gamma 4 (IgG4).
- the light chain constant region may be of kappa or lambda type.
- variable region domain V H variable region domain
- constant region domains CH1, CH2 and CH3 constant region domains
- amino acid sequence having sufficient variable region sequence to confer specificity to the antigen Both heavy chain and fragments thereof.
- light chain refers to a full-length light chain and fragment thereof comprising a variable region domain V L and a constant region domain CL comprising an amino acid sequence having sufficient variable region sequence to confer specificity to the antigen. Means all.
- Antibodies of the invention include monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain Fvs (scFV), single chain antibodies, Fab fragments, F (ab ') fragments, disulfide-binding Fvs (sdFV) And anti-idiotype (anti-Id) antibodies, or epitope-binding fragments of the antibodies, and the like.
- Said monoclonal antibody refers to the same except for possible naturally occurring mutations in which antibodies obtained from substantially homogeneous antibody populations, ie, individual antibodies in the population, may be present in trace amounts.
- Monoclonal antibodies are highly specific and are directed against a single antigenic site. In contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
- Epitope refers to a protein determinant to which an antibody can specifically bind.
- Epitopes usually consist of a group of chemically active surface molecules, such as amino acids or sugar side chains, and generally have specific three dimensional structural characteristics as well as specific charge characteristics. Three-dimensional epitopes and non-stereo epitopes are distinguished in that the binding to the former is lost but not to the latter in the presence of a denatured solvent.
- Non-human (eg murine) antibodies of the “humanized” form are chimeric antibodies that contain minimal sequences derived from non-human immunoglobulins.
- humanized antibodies are non-human species (donor antibodies) that retain the desired specificity, affinity, and capacity for residues from the hypervariable region of the recipient, for example mice, rats, rabbits, or non-humans.
- donor antibodies non-human species
- Human immunoglobulins (receptor antibodies) replaced with residues from the hypervariable regions of primates.
- human antibody refers to a molecule derived from human immunoglobulin, in which all amino acid sequences constituting the antibody including complementarity determining regions and structural regions are composed of human immunoglobulins.
- While the heavy and / or light chain portions are the same or homologous to the corresponding sequences in an antibody derived from a particular species or belonging to a particular antibody class or subclass, the remaining chain (s) are derived from another species or another antibody class or Included are "chimeric" antibodies (immunoglobulins) that are identical or homologous to the corresponding sequences in antibodies belonging to the subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
- antibody variable domain refers to the light and heavy chain portions of an antibody molecule comprising the amino acid sequences of complementarity determining regions (CDRs; ie CDR1, CDR2, and CDR3), and framework regions (FR). .
- CDRs complementarity determining regions
- FR framework regions
- V H refers to the variable domain of the heavy chain.
- V L refers to the variable domain of the light chain.
- CDRs Complementarity Determining Regions
- the present invention includes a heavy chain variable region comprising a heavy chain CDR3 of SEQ ID NO: 1 and a light chain variable region comprising a light chain CDR3 of SEQ ID NO: 2.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 is a heavy chain CDR1 selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 7, heavy chain CDR2 selected from the group consisting of SEQ ID NO: 8 to SEQ ID NO: 15 And a heavy chain variable region comprising a heavy chain CDR3 selected from the group consisting of SEQ ID NOs: 16 to 25, and a light chain CDR1 selected from the group consisting of SEQ ID NOs: 88 to SEQ ID NO: 102, SEQ ID NOs: 103 to 119 Light chain CDR2 selected from the group, and light chain variable region comprising a light chain CDR3 selected from the group consisting of SEQ ID NO: 120 to SEQ ID NO: 144.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 is a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 8, and a heavy chain CDR3 of SEQ ID NO: 16,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 18,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 10, and a heavy chain CDR3 of SEQ ID NO: 19,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 11, and a heavy chain CDR3 of SEQ ID NO: 20,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 21,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 6, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 22,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 23,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 24,
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 15, and a heavy chain CDR3 of SEQ ID NO: 25, or
- the heavy chain variable region may include a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 is a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 88, a light chain CDR2 of SEQ ID NO: 103, and a light chain CDR3 of SEQ ID NO: 120,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 121,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 90, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 122,
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 91, the light chain CDR2 of SEQ ID NO: 106, and the light chain CDR3 of SEQ ID NO: 123,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 107, and a light chain CDR3 of SEQ ID NO: 124,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 92, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 122,
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 93, the light chain CDR2 of SEQ ID NO: 109, and the light chain CDR3 of SEQ ID NO: 125,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 94, a light chain CDR2 of SEQ ID NO: 110, and a light chain CDR3 of SEQ ID NO: 126,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 95, a light chain CDR2 of SEQ ID NO: 111, and a light chain CDR3 of SEQ ID NO: 127,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 96, a light chain CDR2 of SEQ ID NO: 112, and a light chain CDR3 of SEQ ID NO: 128,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 129,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 130,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 113, and a light chain CDR3 of SEQ ID NO: 131,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 97, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 132,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 133,
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, light chain CDR2 of SEQ ID NO: 114, and light chain CDR3 of SEQ ID NO: 134,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 92, a light chain CDR2 of SEQ ID NO: 115, and a light chain CDR3 of SEQ ID NO: 135,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 98, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 130,
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 116, and the light chain CDR3 of SEQ ID NO: 121,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 136,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 99, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 137,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 117, and a light chain CDR3 of SEQ ID NO: 138,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 118, and a light chain CDR3 of SEQ ID NO: 133,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 119, and a light chain CDR3 of SEQ ID NO: 139,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 100, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 140,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 141,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 139,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 142,
- a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 143,
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 101, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 141, or
- a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 102, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 144.
- the antibody or antigen binding fragment thereof according to the invention may comprise:
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 8, and the heavy chain CDR3 of SEQ ID NO: 16, and the light chain CDR1 of SEQ ID NO: 88, the light chain CDR2 of SEQ ID NO: 103, and the light chain CDR3 of SEQ ID NO: 120;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 121;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 18, and the light chain CDR1 of SEQ ID NO: 90, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 122
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 3, the heavy chain CDR2 of SEQ ID NO: 10, and the heavy chain CDR3 of SEQ ID NO: 19, the light chain CDR1 of SEQ ID NO: 91, the light chain CDR2 of SEQ ID NO: 106, and the light chain CDR3 of SEQ ID NO: 123;
- a light chain variable region comprising;
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 11, and a heavy chain CDR3 of SEQ ID NO: 20 and a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 107, and a light chain CDR3 of SEQ ID NO: 124;
- a light chain variable region comprising;
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 21 and a light chain CDR1 of SEQ ID NO: 92, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 122
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 6, the heavy chain CDR2 of SEQ ID NO: 13, and the heavy chain CDR3 of SEQ ID NO: 22, the light chain CDR1 of SEQ ID NO: 93, the light chain CDR2 of SEQ ID NO: 109, and the light chain CDR3 of SEQ ID NO: 125;
- a light chain variable region comprising;
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 23 and a light chain CDR1 of SEQ ID NO: 94, a light chain CDR2 of SEQ ID NO: 110, and a light chain CDR3 of SEQ ID NO: 126
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 7, the heavy chain CDR2 of SEQ ID NO: 14, and the heavy chain CDR3 of SEQ ID NO: 24, and the light chain CDR1 of SEQ ID NO: 95, the light chain CDR2 of SEQ ID NO: 111, and the light chain CDR3 of SEQ ID NO: 127;
- a light chain variable region comprising; or
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 15, and the heavy chain CDR3 of SEQ ID NO: 25, the light chain CDR1 of SEQ ID NO: 96, the light chain CDR2 of SEQ ID NO: 112, and the light chain CDR3 of SEQ ID NO: 128 Light chain variable region containing.
- an antibody was further selected through an optimization process, and the antibody or antigen-binding fragment thereof according to the present invention may include the following heavy chain variable region and light chain variable region:
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108, and the light chain CDR3 of SEQ ID NO: 129;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 130
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 113, and the light chain CDR3 of SEQ ID NO: 131;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 132;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 133;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 114, and the light chain CDR3 of SEQ ID NO: 134;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 92, the light chain CDR2 of SEQ ID NO: 115, and the light chain CDR3 of SEQ ID NO: 135;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 98, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 130
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 116, and the light chain CDR3 of SEQ ID NO: 121;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108, and the light chain CDR3 of SEQ ID NO: 136
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 99, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 137;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 117, and the light chain CDR3 of SEQ ID NO: 138;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 118, and the light chain CDR3 of SEQ ID NO: 133;
- a light chain variable region comprising;
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17, a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 119, and a light chain CDR3 of SEQ ID NO: 139;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 100, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 140;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108, and the light chain CDR3 of SEQ ID NO: 141;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 139;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 142;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 143;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 101, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 141;
- a light chain variable region comprising; or
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17, a light chain CDR1 of SEQ ID NO: 102, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 144; Light chain variable region containing.
- the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17, and a light chain CDR1 of SEQ ID NO: 89, sequence A light chain variable region comprising the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 121;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 130
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 133;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108, and the light chain CDR3 of SEQ ID NO: 136
- a light chain variable region comprising;
- a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17, a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 119, and a light chain CDR3 of SEQ ID NO: 139;
- a light chain variable region comprising;
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, and the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 139;
- a light chain variable region comprising; or
- a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9, and the heavy chain CDR3 of SEQ ID NO: 17, the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105, and the light chain CDR3 of SEQ ID NO: 143; It may include a light chain variable region comprising.
- FRs Framework regions
- Each variable domain typically has four FRs identified as FR1, FR2, FR3 and FR4.
- the heavy chain variable region FR1 selected from the group consisting of SEQ ID NO: 26 to SEQ ID NO: 34,
- a heavy chain variable region FR2 selected from the group consisting of SEQ ID NOs: 35 to 41;
- a heavy chain variable region FR3 selected from the group consisting of SEQ ID NOs: 42 to 49, or
- It may comprise a heavy chain variable region FR4 selected from the group consisting of SEQ ID NO: 50 to SEQ ID NO: 54.
- the light chain variable region FR1 selected from the group consisting of SEQ ID NOs: 145 to 163,
- Light chain variable region FR2 selected from the group consisting of SEQ ID NOs: 164 to 184,
- Light chain variable region FR3 selected from the group consisting of SEQ ID NOs: 185 to 210, or
- the light chain variable region FR4 selected from the group consisting of SEQ ID NOs: 211 to 216 may be included.
- Fv fragments are antibody fragments containing complete antibody recognition and binding sites. This region consists of a dimer of one heavy chain variable domain and one light chain variable domain tightly and covalently associated, for example, with scFv.
- Fab fragments contain the variable and constant domains of the light chain and the variable and first constant domains (CH1) of the heavy chain.
- F (ab ') 2 antibody fragments generally comprise a pair of Fab fragments covalently linked near their carboxy termini by hinge cysteines between them.
- Single-chain Fv or “scFv” antibody fragments comprise the V H and V L domains of an antibody, which domains are present in a single polypeptide chain.
- the Fv polypeptide may further comprise a polypeptide linker between the V H domain and the V L domain that allows the scFv to form the desired structure for antigen binding.
- the binding affinity of the PD-L1 antibody is in the range of 10 ⁇ 5 M to 10 ⁇ 12 M.
- the binding affinity of PD-L1 antibody is 10 -6 M to 10 -12 M, 10 -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11 M, 10 -5 M to 10 -10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10
- the antibody or antigen-binding fragment thereof that binds to PD-L1 may include a heavy chain variable region comprising a sequence having 90% or more sequence homology with a sequence selected from the group consisting of SEQ ID NO: 57 to SEQ ID NO: 87.
- the antibody or antigen binding fragment thereof that binds to PD-L1 may comprise a heavy chain variable region selected from the group consisting of SEQ ID NO: 57 to SEQ ID NO: 87.
- the heavy chain variable region of SEQ ID NO: 58, 68, 71, 76, 80, 83 or 85 may be included.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 may comprise a light chain variable region comprising a sequence having 90% or more sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 217 to 247. have.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 may comprise a light chain variable region selected from the group consisting of SEQ ID NO: 217 to SEQ ID NO: 247.
- the light chain variable region of SEQ ID NO: 218, 228, 231, 236, 240, 243 or 245 may be included.
- the heavy chain variable region of SEQ ID NO: 85 and the light chain variable region of SEQ ID NO: 245 may be included.
- Phase display is a technique for displaying variant polypeptides as phage proteins, such as fusion proteins with at least a portion of the envelope protein on the surface of fibrous phage particles.
- the utility of phage display lies in the fact that a large library of randomized protein variants can be targeted to quickly and efficiently classify sequences that bind with high affinity with a target antigen. Displaying peptide and protein libraries on phage has been used to screen millions of polypeptides to identify polypeptides with specific binding properties.
- Phage display technology provided a powerful tool for generating and selecting new proteins that bind specific ligands (eg antigens). Phage display technology can be used to generate large libraries of protein variants and to quickly sort sequences that bind with high affinity to target antigens.
- Nucleic acids encoding variant polypeptides are fused with nucleic acid sequences encoding viral envelope proteins, eg, gene III protein or gene VIII protein.
- Monovalent phage display systems have been developed in which a nucleic acid sequence encoding a protein or polypeptide is fused with a nucleic acid sequence encoding a portion of a gene III protein. In monovalent phage display systems, gene fusions are expressed at low levels and wild type Gene III proteins are also expressed to maintain particle infectivity.
- Phage display technology has several advantages over conventional hybridoma and recombinant methods for preparing antibodies with the desired characteristics. This technique allows the production of large antibody libraries with various sequences in a short time without the use of animals. The preparation of hybridomas or the production of humanized antibodies may require months of preparation. In addition, since no immunity is required at all, phage antibody libraries can produce antibodies against antigens that are toxic or low antigenic. Phage antibody libraries can also be used to generate and identify novel therapeutic antibodies.
- Techniques for generating human antibodies from immunized, non-immunized human, germline sequences, or na ⁇ ve B cell Ig repertory using immunized phage display libraries can be used.
- Various lymphoid tissues can be used to prepare na ⁇ ve or non-immune antigen binding libraries.
- the ability to identify and isolate high affinity antibodies from phage display libraries is important for the isolation of novel therapeutic antibodies. Separation of high affinity antibodies from the library may depend on the size of the library, the efficiency of production in bacterial cells, and the diversity of the library.
- the size of the library is reduced by inefficient folding of the antibody or antigen binding protein and inefficient production due to the presence of stop codons. Expression in bacterial cells can be inhibited if the antibody or antigen binding domain is not properly folded. Expression can be improved by alternating mutations at the surface of the variable / constant interface or at selected CDR residues.
- the sequence of the backbone region is one element to provide proper folding when generating antibody phage libraries in bacterial cells.
- CDR3 regions have been found to often participate in antigen binding.
- the CDR3 regions on the heavy chains vary considerably in size, sequence, and structural conformation, and thus can be used to prepare a variety of libraries.
- diversity can be generated by randomizing the CDR regions of the variable heavy and light chains using all 20 amino acids at each position.
- the use of all twenty amino acids can result in highly variable variant antibody sequences and increase the chance of identifying new antibodies.
- the antibody or antibody fragment of the present invention may include not only the sequences of the anti-PD-L1 antibodies of the present invention, but also biological equivalents thereof, as long as they specifically recognize PD-L1.
- further changes can be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody.
- Such modifications include, for example, deletions, insertions and / or substitutions of amino acid sequence residues of the antibody.
- Such amino acid variations are made based on the relative similarity of amino acid side chain substituents such as hydrophobicity, hydrophilicity, charge, size, and the like.
- arginine, lysine and histidine are all positively charged residues; Alanine, glycine and serine have similar sizes; It can be seen that phenylalanine, tryptophan and tyrosine have a similar shape.
- arginine, lysine and histidine; Alanine, glycine and serine; Phenylalanine, tryptophan and tyrosine are biologically equivalent functions.
- the antibody or nucleic acid molecule encoding the same of the present invention is interpreted to include a sequence that exhibits substantial identity with the sequence described in SEQ ID NO.
- the above substantial identity is at least 90% when the sequences of the present invention are aligned as closely as possible with any other sequences, and the aligned sequences are analyzed using algorithms commonly used in the art.
- a homology most preferably at least 95% homology, at least 96%, at least 97%, at least 98%, at least 99% homology. Alignment methods for sequence comparison are known in the art.
- BLAST The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI and the like and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn and tblastx on the Internet.
- BLSAT is accessible at www.ncbi.nlm.nih.gov/BLAST/. Sequence homology comparisons using this program can be found at www.ncbi.nlm.nih.gov/BLAST/blast_help.html.
- the antibody or antigen-binding fragment thereof of the present invention is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% compared to the specified sequence or all described in the specification. , 99%, or more homology.
- homology can be determined by sequence comparison and / or alignment by methods known in the art. For example, sequence comparison algorithms (ie, BLAST or BLAST 2.0), manual alignment, visual inspection can be used to determine the percent sequence homology of nucleic acids or proteins of the invention.
- the present invention relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof.
- the nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention can be isolated to recombinantly produce the antibody or antigen-binding fragment thereof.
- the nucleic acid is isolated and inserted into a replicable vector for further cloning (amplification of DNA) or for further expression. Based on this, the present invention relates to a vector comprising the nucleic acid in another aspect.
- Nucleic acid is meant to encompass DNA (gDNA and cDNA) and RNA molecules inclusively, and the nucleotides that are the basic building blocks of nucleic acids include natural nucleotides as well as analogs with modified sugar or base sites. .
- the sequences of nucleic acids encoding heavy and light chain variable regions of the invention can be modified. Such modifications include addition, deletion, or non-conservative or conservative substitutions of nucleotides.
- the DNA encoding the antibody is readily isolated or synthesized using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to the DNA encoding the heavy and light chains of the antibody).
- Many vectors are available.
- Vector components generally include, but are not limited to, one or more of the following: signal sequence, origin of replication, one or more marker genes, enhancer elements, promoters, and transcription termination sequences.
- the term "vector” refers to a plasmid vector as a means for expressing a gene of interest in a host cell; Cosmid vector; Viral vectors such as bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors, and the like.
- the nucleic acid encoding the antibody in the vector is operably linked with a promoter.
- “Operatively linked” means a functional binding between a nucleic acid expression control sequence (eg, an array of promoters, signal sequences, or transcriptional regulator binding sites) and another nucleic acid sequence, whereby the regulatory sequence is the other nucleic acid. To control transcription and / or translation of the sequence.
- a nucleic acid expression control sequence eg, an array of promoters, signal sequences, or transcriptional regulator binding sites
- promoters capable of promoting transcription e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL ⁇ promoter, pR ⁇ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- ribosome binding sites for initiation of translation e.g., amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- a promoter derived from the genome of the mammalian cell e.g., a metallothionine promoter, a ⁇ -actin promoter, a human heroglobin promoter and a human muscle creatine promoter
- a mammal Promoters derived from animal viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse breast tumor virus (MMTV) promoter, LTR promoter of HIV
- a promoter derived from the genome of the mammalian cell e.g., a metallothionine promoter, a ⁇ -actin promoter, a human heroglobin promoter and a human muscle creatine promoter
- a mammal Promoters derived from animal viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter
- the vector may be fused with other sequences to facilitate purification of the antibody expressed therefrom.
- Sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
- Such vectors include antibiotic resistance genes commonly used in the art as selectable markers and include, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. There is a resistance gene.
- the present invention relates to a cell transformed with the above-mentioned vector.
- the cells used to produce the antibodies of the invention can be prokaryote, yeast or higher eukaryote cells, but are not limited thereto.
- Bacillus strains such as Escherichia coli, Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g. Pseudomonas putida), Proteus Prokaryotic host cells such as Proteus mirabilis and Staphylococcus (eg, Staphylocus carnosus) can be used.
- Pseudomonas e.g. Pseudomonas putida
- Proteus Prokaryotic host cells such as Proteus mirabilis and Staphylococcus (eg, Staphylocus carnosus) can be used.
- examples of useful host cell lines are COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0 , U20S, or HT1080, but is not limited thereto.
- the present invention (a) culturing the cells; And (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.
- the cells can be cultured in various media. It can be used as a culture medium without limitation among commercial media. All other necessary supplements known to those skilled in the art may be included at appropriate concentrations. Culture conditions, such as temperature, pH, and the like, are already in use with host cells selected for expression, which will be apparent to those skilled in the art.
- the recovery of the antibody or antigen-binding fragment thereof can be removed by, for example, centrifugation or ultrafiltration, and the resultant can be purified using, for example, affinity chromatography or the like. Further other purification techniques such as anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and the like can be used.
- the present invention relates to a composition for preventing or treating cancer, which comprises the antibody as an active ingredient.
- the present invention includes, for example, (a) a pharmaceutically effective amount of an antibody against PD-L1 or an antigen binding fragment thereof according to the present invention; And (b) it may be a pharmaceutical composition for the prevention or treatment of cancer or infectious diseases comprising a pharmaceutically acceptable carrier.
- the present invention also relates to a method for the prophylaxis or treatment of cancer or infectious disease comprising administering to a patient an effective amount necessary for an antibody against PD-L1 or an antigen-binding fragment thereof.
- composition uses the above-described anti-PD-L1 antibody or antigen-binding fragment thereof as an active ingredient, the description in common between the two is omitted.
- T cell depletion is a condition of T cell dysfunction that can occur in chronic infections and cancer. It is defined as poor effector function, sustained expression of inhibitory receptors, and transcriptional states that are different from functional effector or memory T cells. Depletion interferes with the management of infection and tumor progression.
- the antibodies or antigen-binding fragments thereof of the present invention bind to PD-L1 with high affinity and inhibit the formation of PD-1 and PD-L1 complexes, thereby avoiding anti-tumor T cell activity. It can be usefully used to treat cancer that induces T cell depletion.
- anticancer therapeutic agents in addition to the above antibodies can effectively target tumor cells overexpressing PD-L1, increase anti-tumor T cell activity, and enhance the immune response targeting tumor cells.
- Other anti-neoplastic or immunogenic agents eg, weakened cancer cells, tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), antigen-transmitting cells, eg, tumor-derived antigens or nucleic acids
- VEGF VEGF, EGFR, Her2 / neu, VEGF receptors,
- Anti PD-L1 antibodies can induce cell death.
- Cell death is induced by direct or indirect mechanisms.
- PD-L1 binding by anti PD-L1 antibodies can result in complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- the anti-PD-L1 antibody binds to PD-L1 and results in the recruitment of secondary cell types that will kill PD-L1 expressing target cells.
- Representative mechanisms by which anti-PD-L1 antibodies mediate cell death by recruitment of secondary cell types include, but are not limited to, antibody dependent cytotoxicity (ADCC) and antibody dependent cell phagocytosis (ADCP).
- Target PD-L1 expressing cell types include tumors and T cells, for example activated T cells.
- antibodies or antibody fragments of the invention can be used to prevent or treat infections and infectious diseases.
- Prevention means any action that inhibits or delays the progression of cancer or infectious disease by administration of a composition according to the present invention
- treatment means inhibiting cancer development, reducing or eliminating cancer, or infection Inhibition of disease, reduction of infectious disease or removal of infectious disease.
- Cancers which are diseases to which the composition is applied include cancers that typically respond to immunotherapy, and cancers that are not related to immunotherapy so far.
- Non-limiting examples of preferred cancers for treatment include melanoma (eg metastatic malignant melanoma), kidney cancer (eg clear cell carcinoma), prostate cancer (eg hormonal refractory prostate carcinoma), Pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer (eg, non-small cell lung cancer), esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma, and other kidneys Includes biological carcinoma.
- the present invention includes refractory or recurrent cancer that can inhibit growth using the antibodies of the present invention.
- the antibody or antibody fragment can be used alone or in combination with a vaccine to stimulate an immune response to pathogens, toxins, and self-antigens.
- Antibodies or antigen-binding fragments thereof include, for example, human immunodeficiency virus, hepatitis virus classes A, B and C, Eppstein Barr virus, human cytomegalovirus, human papilloma Virus, Herpes Virus, can be used to stimulate an immune response against a virus that infects a human, including but not limited to.
- Antibodies or antigen-binding fragments thereof can be used to stimulate an immune response to infection of bacterial or fungal parasites, and other pathogens.
- compositions of the present invention are those commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like in addition to the above components.
- composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, pulmonary administration and rectal administration Or the like.
- oral compositions should be formulated to coat the active agent or to protect it from degradation in the stomach.
- the pharmaceutical composition may be administered by any device in which the active agent may migrate to the target cell.
- Suitable dosages of the compositions according to the invention vary depending on factors such as the method of formulation, mode of administration, age, weight, sex, morbidity, condition of the patient, food, time of administration, route of administration, rate of excretion and reaction sensitivity, and usually The skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
- the daily dose of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg.
- pharmaceutically effective amount as used herein means an amount sufficient to prevent or treat cancer.
- compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of extracts, powders, suppositories, powders, granules, tablets, or capsules, and may further include a dispersant or stabilizer.
- compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents.
- the present invention is a cancer diagnostic composition comprising an antibody against PD-L1 according to the present invention.
- the present invention also relates to a method for diagnosing cancer by treating an antibody against PD-L1 or an antigen-binding fragment thereof according to the present invention.
- Cancer can be diagnosed by measuring PD-L1 expression levels in a sample via an antibody against PD-L1 according to the invention.
- Expression levels can be measured according to conventional immunoassay methods, radioimmunoassay using the antibody against PD-L1, radioimmunoprecipitation, immunoprecipitation, immunohistochemical staining, enzyme-linked immunosorbant assay (ELISA), capture -ELISA, inhibition or hardwood analysis, sandwich analysis, flow cytometry, immunofluorescence staining and immunoaffinity purification can be measured, but is not limited thereto.
- cancer By analyzing the final signal intensity by the immunoassay process, cancer can be diagnosed. That is, if the protein of the marker of the present invention is expressed high in a biological sample and the signal is stronger than that of the normal biological sample (eg, normal gastric tissue, blood, plasma or serum), the cancer is diagnosed.
- the normal biological sample eg, normal gastric tissue, blood, plasma or serum
- the present invention relates to a cancer diagnostic kit comprising the cancer diagnostic composition.
- the kit according to the present invention comprises an antibody against PD-L1 according to the present invention, and can diagnose cancer by analyzing a signal indicated by the reaction between the sample and the antibody.
- the signal may include, but is not limited to, an enzyme bound to the antibody, for example, alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, luciferase or cytochrome P450.
- the substrate for the enzyme is bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol) as the substrate.
- BCIP bromochloroindolyl phosphate
- NBT nitro blue tetrazolium
- naphthol-AS-B1-phosphate naphthol
- Chloronaphthol aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin when color development reaction substrates such as -AS-B1-phosphate) and enhanced chemifluorescence (ECF) are used, and horse radish peroxidase is used (Bis-N-methylacridinium nitrate), resorphin benzyl ether, luminol, amplex red reagent (10-acetyl-3,7-dihydroxyphenoxazine), HYR (p-phenylenediamine-HCl and pyr ocatechol), TMB (tetramethylbenzidine), ABTS (2,2'-Azine-di [3-ethylbenzthiazoline sulfonate]), o-phenylenediamine (OPD) and naphthol / pyronine, glucose oxidase and t-NBT (nitroblue tetrazolium)
- kits according to the invention may comprise a label which generates a detectable signal, said label comprising a chemical (eg biotin), an enzyme (alkaline phosphatase, ⁇ -galactosidase, horse radish). Peroxidase and cytochrome P450), radioactive materials (eg C14, I125, P32 and S35), fluorescent materials (eg fluorescein), luminescent materials, chemiluminescent and fluorescence resonance energy transfer (FRET) It may include, but is not limited thereto.
- a chemical eg biotin
- an enzyme alkaline phosphatase, ⁇ -galactosidase, horse radish
- Peroxidase and cytochrome P450 cytochrome P450
- radioactive materials eg C14, I125, P32 and S35
- fluorescent materials eg fluorescein
- luminescent materials eg fluorescein
- FRET fluorescence resonance energy transfer
- Measurement of the activity or signal of an enzyme used for cancer diagnosis can be carried out according to various methods known in the art. This allows for either qualitative or quantitative analysis of PD-L1 expression.
- Plasmid DNA was transfected into HEK-293F cells to express the antigen in animal cells.
- the polyplex reaction solution for transfection was performed by mixing 25 ⁇ g of plasmid DNA in 3 ml of Freestyle 293 expression medium and further adding 2 mg / ml PEI (Polyethylenimine) (polyplUSA-transfection, USA). ) 50 ⁇ l and mix again.
- the polyplex reaction solution was reacted at room temperature for 15 minutes, and then placed in a 40 ml culture medium incubated at 1 ⁇ 10 6 cells / ml and incubated at 120 rpm at 37 ° C. and 8% CO 2 for 24 hours.
- the protein When using recombinant Protein A agarose resin, the protein was eluted with 0.1M glycine and neutralized with 500 ⁇ l of 1M Tris-HCl, and the first purified protein was a Superdex 200 (1.5 cm * 100 cm) gel. Secondary purification was performed using filtration chromatography.
- Purified protein was purified by SDS-PAGE gel and size exclusion chromatography (TSK-GEL G-3000 SWXL Size-exclusion chromatography (SEC) (Tosoh)).
- Example 1 50 ug of PD-L1-hFc, PD-L1-mFc and PD-L1-his (Catalog Number, 10084-H08H) protein antigen prepared in Example 1 were coated on an immunosorbent tube After blocking was performed.
- the phage were infected with bacteria with a human scFv library with a variety of 2.7 ⁇ 10 10 , and the bacteria were incubated at 30 ° C. for 16 hours. After incubation, the supernatant was concentrated by PEG, and then dissolved in PBS buffer to prepare a human antibody library. After the library phage was put into the immunotube, the reaction was carried out at room temperature for 2 hours, and then washed with 1XPBS / T and 1XPBS to elute only scFv-phage specifically bound to the antigen.
- the pool of positive phages is obtained through the panning process of infecting and eluting the eluted phages again.
- the amplified phages are increased and only the number of times in the PBST washing step is used. Round panning was performed. As a result, it was confirmed that the output of the phage bound to the antigen was slightly increased compared to the input in the third round panning as shown in Table 2.
- each well was washed with 0.2 ml of PBS / T, and then 100 ⁇ l of the first to third panning poly scFv-phage was added to each well and allowed to react at room temperature for 2 hours. Again, each well was washed four times with 0.2 ml of PBS / T, and then the secondary antibody anti-M13-HRP (Amersham 27-9421-01) was diluted 1: 2000 and reacted at room temperature for 1 hour. After washing with PBS / T, OPD tablet (sigma. 8787-TAB) was made into PC buffer, 100 ul / well each color developed for 10 minutes, and absorbance was measured with a spectrophotometer (Molecular Device) at 490 nm.
- OPD tablet sigma. 8787-TAB
- Colonies from high-binding polyclonal phage antibody groups were incubated for 16 hours at 37 ° C. in 1 ml 96-deep well plates (Bionia 90030) in 2 ⁇ YTCM, 2% glucose, 5 mM MgCl 2 medium. Take 100-200 ul of cells so that the value is 0.1 at OD 600 in these grown cells and place in 1 ml of 2xYTCM, 2% glucose, 5 mM MgCl 2 medium, and then measure the value at OD 600 at 37 ° C in a 96-deep well plate. Incubate for 2-3 hours so that it is 0.5-0.7. M1 helper phages were infected with a MOI of 1:20 and incubated for 16 hours at 30 ° C. in 2 ⁇ YTCMK, 5 mM MgCl 2 1 mM IPTG medium.
- Each well was blocked using 4% skim milk dissolved in PBS after coating 100 ng of antigen PD-L1 per well for 16 hours at 4 ° C. in a 96 well immune plate.
- 100 ⁇ l of monoclonal scFv-phage (100 scFv-phage) incubated for 16 hours washed with 0.2 ml PBS / T in each well was added to each well and allowed to react at room temperature for 2 hours.
- Each well was washed four times with 0.2 ml PBS / T, and then the second antibody, anti-M13-HRP, was diluted to 1/2000 and reacted at room temperature for 1 hour. After washing with 0.2 ml PBS / T, color development was measured at 490 nm.
- the selected clones were subjected to DNA-prep using a DNA purification kit (Qiagen, Germany) to obtain DNA and to request sequencing (solgent). Based on the results of the sequencing analysis, the CDR sites of V H and V L of the selected antibodies were identified, and the similarity between these antibodies and the germ line antibody group was determined by NCBI's web page http: //www.ncbi.nlm.nih.
- the Ig BLAST program at .gov / igblast / was used to investigate. As a result, phage antibodies specific for 10 PD-L1 were obtained, which are summarized in Table 3 below.
- the antibodies comprising the heavy and light chain CDRs, FR sequences, and the heavy chain variable region and the light chain variable region comprising the selected antibodies are shown in Tables 4 and 5.
- PCR (iCycler iQ, BIO-RAD) was performed on the heavy and light chains to convert monoclonal phage antibodies against selected 1110 PD-L1 phages into IgG whole vectors.
- heavy and light chains were obtained, and the heavy and light chains of the vector and each clone were cleaved with restriction enzymes.
- the vector and heavy chains were each eluted with a DNA-gel extraction kit (Qiagen).
- Ligation is a mixture of vector 1 ul (10 ng) heavy chain (100-200 ng) 15 ul, 10x Buffer 2 ul, ligase (1 U / ul) 1 ul, distilled water and left at room temperature for 1-2 hours. , Transformed into cells (competent cells) (XL1-blue) and placed on ice for 5 minutes, gave a heat shock (heat shock) at 42 °C for 90 seconds.
- the cloned pNATVH and pNATVL vectors were cotransfected (co-transfected) into HEK293F cells at a ratio of 6: 4, and the supernatant was collected on day 7 to remove cells and suspended solids through centrifugation and a 0.22 ⁇ m top-filter. The supernatants were collected and protein A affinity chromatography was performed to purify IgG antibodies. After purification, the antibody was isolated through glycine buffer, and the buffer was exchanged so that the final resuspension buffer became PBS. Purified antibodies were quantified by BCA and nano drop, and 15 antibodies were loaded at 5 ug each under reduced and non-reduced conditions, and subjected to SDS-PAGE analysis for purity and mobility of purified proteins. It was confirmed (Fig. 5).
- PD1 / PD-L1 blocking bioassay kit Promega, J1250.
- CHO cell line with high expression of PD-L1 was plated in a 96-well plate, cultured for 16 hours or more, treated with each antibody serially diluted to a constant concentration, and Jurkat cell line with high expression of human PD-1 for 6 hours. Incubated together.
- the degree of recovery of inhibition of the antibody was determined by the intensity of luminescence produced by luciferase decomposing the substrate and measured by a spectrophotometer (SpectraMax M5 spectraphotometer, Molecular Devices, USA).
- Ten PD-L1 antibodies confirmed the activity of the antibody to restore the signal reduced by PD-1 / PD-L1 complex formation, 16E12 showed similar activity compared to the control antibody (Fig. 6).
- the dilution of the PD-1 / PD-L1 blocking bioassay was carried out to recover the reduced signal in a concentration gradient dependent manner.
- the degree of recovery can be represented as EC50 (effective concentration of mAb at 50% level of Recovery signal) and analyzed using Graphpad Prism6 of EC50 in vitro efficacy inhibit recovery capability is shown in FIG.
- Transgenic cell pools expressing PD-L1 were transformed to HEK293E with a pcDNA3.1 plasmid containing human PD-L1 and screened in selective medium containing 150 ug / ml Zeocin (# R25001, Thermo Fisher). It was. Each cell pool was identified and selected by fluorescence activated cell sorting (FACS) analysis using each anti-PD-L1, and used for functional evaluation methods such as FACS binding assays and FACS competition assays.
- FACS fluorescence activated cell sorting
- Each transgenic cell pool expressing human PD-L1 was prepared with 0.5-1x10 ⁇ 6 cells per sample, and the antibodies were continuously diluted in constant dilution multiples and reacted with the prepared cells at 4 ° C. for 20 minutes. The cells were then washed three times with PBS (# LB001-02, welgene) containing 2% fetal bovine serum, and the anti-human IgG antibody (#ITC) bound to the fluorescein isothiocyanate (FITC) phosphor FI-3000, Vectorlabs) and reacted at 4 ° C.
- PBS # LB001-02, welgene
- ITC anti-human IgG antibody
- FITC fluorescein isothiocyanate
- the binding force of the antibody bound in a concentration-dependent manner to human PD-L1 overexpressed on the cell surface can be known as mean fluorescence intensity (MFI).
- PBST buffer was used to collect the sensogram data during the binding and dissociation process over time while flowing the antibody for 10 minutes at a flow rate of 30 ul / min at different concentrations (30 nM to 0.123 nM).
- the sensogram data at the equilibrium were plotted and plotted according to the concentration to calculate the equilibrium dissociation constant (K D ), showing a high affinity for the PD-L1 antigen at 0.045 nM (FIG. 9).
- Antibody optimization was performed by constructing a new LC shuffling library by fixing the heavy chain and adding the 105-106 light chain (LC) pool possessed by YBIOLOGICS, and the LC shuffling, hydrophobic core of the heavy chain (LCs were converted to conserved residues by comparison with residues of structurally important sites such as hydrophobic cores, exposed residues, charge clusters and salt bridges.
- Core packing + LC shuffling undergoing shuffling, DNA of antibody variable region is in vivo There are three ways to proceed: affinity maturation, CDR hotspot + LC shuffling, which randomly mutates mutational hot spots that can be frequently muted. It was.
- the LC gene of the 16E12 antibody was cleaved with BstX I and used as a vector, and the library pool retained by WBIOLOGICS was cut with BstX I and used as an insert. After ligation with ligase, transformation was performed using electroporation transformation taxa.
- the antibody libraries were prepared by collecting the transformed cells in a square plate, and various libraries of about 1.5 ⁇ 10 7 were obtained. As a result of sequencing analysis, the sequences of HC were all identical and the sequences of LCs were different.
- the frame work (FR) portion of the 16E12 antibody was replaced with a conserved amanoic acid sequence, followed by cleavage of the LC gene with BstX I and use as a vector.
- the library pool retained at was cut with BstX I and used as an insert.
- transformation was performed using electroporation transformation taxa.
- the antibody libraries were prepared by collecting the transformed cells in a square plate, and various libraries of about 8.4 ⁇ 10 6 were obtained.
- the sequencing analysis showed that the FR sites of HC were substituted with conserved amanoic acid sequences. It was confirmed that the sequence of is different.
- CDR hotspot + LC shuffling library To construct a CDR hotspot + LC shuffling library, the frame work (FR) portion of the 16E12 antibody was replaced with a conserved amanoic acid sequence, the CDR1 hotspot library was cleaved with Sfi I and used as an insert, and then The library pool possessed by Biologics was cut into Sfi I and used as a vector. After ligation with ligase, transformation was performed using the cells for electroporation transformation. The antibody libraries were prepared by collecting the transformed cells in a square plate, and various libraries of about 5.6x106 were obtained, and sequencing showed that the FR sites of HC were substituted with conserved amanoic acid sequences and hotspots of CDR1. It was confirmed that the amino acids of the sequence was randomly changed and the sequence of the LC is different.
- Blocking after coating 50 ug of PD-L1-hFc, PD-L1-mFc and PD-L1-his (Catalog Number, 10377-H08H) protein antigen produced by YBIOLOGICS in immunosorb tube blocking was performed.
- Human Antibody Library Phage was infected with bacteria with a human scFv library of 2.7 ⁇ 10 10 diversity and then incubated at 30 ° C. for 16 hours. After incubation, the supernatant was concentrated by PEG, and then dissolved in PBS buffer to prepare a human antibody library. After the library phage was put into the immunotube, the reaction was carried out at room temperature for 2 hours, and then washed with 1XPBS / T and 1XPBS to elute only scFv-phage specifically bound to the antigen.
- a pool of positive phages was obtained through a panning process in which the eluted phages were again infected with E. coli and amplified, and panning for antibody optimization was performed only the first round.
- the number of phages bound to the antigen in the first round panning was slightly increased compared to the input.
- Colonies from panning were incubated for 16 hours at 37 ° C. in 1 ml 96-deep well plate (Biononia 90030) in 2 ⁇ YTCM, 2% glucose, 5 mM MgCl 2 medium. Take 100-200 ul of cells so that the value is 0.1 at OD 600 in these grown cells and place in 1 ml of 2xYTCM, 2% glucose, 5 mM MgCl 2 medium, and then measure the value at OD 600 at 37 ° C in a 96-deep well plate. It was incubated for 2-3 hours so that it is 0.5-0.7. M1 helper phages were infected with a MOI of 1:20 and incubated for 16 hours at 30 ° C. in 2 ⁇ YTCMK, 5 mM MgCl 2 1 mM IPTG medium.
- the selected monoclones were subjected to DNA-prep using a DNA purification kit (Qiagen, Germany) to obtain DNA and to request sequencing (solgent). Based on the results of the sequencing analysis, the CDR regions of V H and V L of the selected antibodies were identified, and the similarity between these antibodies and germ line antibody group was determined by NCBI's web page http://www.ncbi.nlm.nih.gov/igblast Investigation using the Ig BLAST program of / resulted in a specific phage antibody having a higher binding capacity than the 21 parent antibodies, which are summarized in Table 7 below.
- the antibodies comprising the heavy and light chain CDRs, FR sequences, and heavy chain variable regions and light chain variable regions comprising the selected antibodies are shown in Tables 8 and 9 below.
- PCR iCycler iQ, BIO-RAD
- iCycler iQ BIO-RAD
- PCR was performed on the heavy and light chains to convert monoclonal phage antibodies against 21 selected PD-L1 phages into IgG whole vectors.
- heavy and light chains were obtained, and the restriction enzymes cut the heavy and light chains of the vector and the individual clones.
- Each vector and heavy chain was eluted with a DNA-gel extraction kit (Qiagen).
- Ligation is a vector of 1 ul (10 ng) heavy chain (100-200 ng) 15 ul, 10x buffer 2 ul, ligase (1 U / ul) 1 ul, distilled water and mixed for 1 to 2 hours at room temperature Then, put into transformed cells (competent cells: XL1-blue) and placed on ice for 5 minutes, gave a heat shock (heat shock) at 42 °C for 90 seconds.
- the cloned pNATVH and pNATVL vectors were cotransfected (co-transfected) into HEK293F cells at a ratio of 6: 4, and the supernatant was collected on day 7 to remove cells and suspended solids through centrifugation and a 0.22 ⁇ m top-filter.
- the supernatants were collected and protein A affinity chromatography was performed to purify IgG antibodies. After purification, the antibody was isolated through glycine buffer, and the buffer was exchanged so that the final resuspension buffer became PBS.
- Purified antibodies were quantified by BCA and nano drop, and 21 antibodies were loaded by 5 ug each for reducing and non-reducing conditions, followed by SDS-PAGE analysis for purity and mobility of purified proteins. The state was confirmed. In addition, a portion of the supernatant was loaded on SDS-PAGE to compare the expression rate with the parent antibody, and most of the antibodies showed higher expression rate than the parent antibody.
- PD-1 / PD-L1 block bioassay kit Promega, J1250.
- CHO cell line with high expression of PD-L1 was plated in a 96-well plate, cultured for 16 hours or more, treated with each antibody serially diluted to a constant concentration, and Jurkat cell line with high expression of human PD-1 for 6 hours. Incubated together.
- the extent of recovery of inhibition of the antibody was determined by the luminescence intensity of luciferase by breaking down the substrate and measured by spectrophotometer (SpectraMax M5 spectraphotometer, Molecular Devices, USA).
- PD-L1 antibodies confirmed the activity of the antibody to restore the signal reduced by PD-1 / PD-L1 complex formation, 4A7, 4A11, 4C9, 4F5, 4H5, 4H8 compared to the parent antibody This increased and showed similar activity compared to the control antibody (FIG. 11 and Table 10).
- the transgenic cell pool expressing human PD-1 was transformed into HEK293E with a pcDNA3.1 plasmid containing human PD-1 (NM_005018.2) or human PD-L1 (NM_014143.2), and 400 ug / Selection was made in selective medium containing ml Zeocin (# R25001, Thermo Fisher). Each cell pool was identified and selected by fluorescence activated cell sorting (FACs) analysis using anti-PD-1 (# 557860, BD), respectively, and used for functional evaluation methods such as FACs binding assays or FACs competition assays. Was used.
- FACs fluorescence activated cell sorting
- Each transgenic cell pool expressing human PD-L1 was prepared with 0.5-1x10 ⁇ 6 cells per sample, and the antibodies were continuously diluted in constant dilution multiples and reacted with the prepared cells at 4 ° C. for 20 minutes. The cells were then washed three times with PBS (# LB001-02, welgene) containing 2% fetal bovine serum, and the anti-human IgG antibody (#ITC) bound to the fluorescein isothiocyanate (FITC) phosphor FI-3000, Vectorlabs) and reacted at 4 ° C.
- PBS # LB001-02, welgene
- ITC anti-human IgG antibody
- FITC fluorescein isothiocyanate
- Each transgenic cell pool expressing human PD-L1 was prepared with 0.5x10 ⁇ 6 cells per sample, and the antibodies were reacted with the prepared cells for 20 min at 4 ° C. by diluting the antibodies serially with a constant dilution factor. The cells were then washed three times with PBS (# LB001-02, welgene) containing 2% fetal bovine serum, and the anti-human IgG antibody (#ITC) bound to the fluorescein isothiocyanate (FITC) phosphor FI-3000, Vectorlabs) and reacted at 4 ° C.
- PBS # LB001-02, welgene
- ITC anti-human IgG antibody
- FITC fluorescein isothiocyanate
- Human PD-1-Fc (S1420, Y-Biologics) was fixed in a well of a 96-well immuno microplate (96-well immunoplate, # 439454, Thermo) at 4 ° C. for 16 hours, and 0.05% tween-20 ( After washing three times with PBS containing # P9416, Sigma-Aldrich), non-specific binding was blocked by standing at room temperature for 1 hour with a wash solution containing 4% skim milk (# 232120, Becton, Dickinson and Company).
- the equilibrium dissociation constant (KD) was calculated by plotting and plotting the sensogram data at equilibrium according to the concentration, and 16E12 (4F5) showed 0.001 nM with high affinity for the PD-L1 antigen. ( Figure 15).
- each antibody serially diluted in a constant dilution multiple or human PD-1-His (S1352, Y-Biologics) used as a positive control was reacted at room temperature for 1 hour, and then placed in a prepared microplate for 1 hour at room temperature. Let's do it.
- the anti-Biotin-His antibody (# MA1-21315-BTIN, Thermo) was diluted 1: 2000 and put in the well of the microplate and reacted at room temperature for 1 hour, and then washed in the same manner
- Streptavidin poly-HRP antibody (# 21140, Pierce) was diluted 1: 5000, put into a well of a microplate, and reacted at room temperature for 1 hour, and washed in the same manner.
- Add 100 ul TMB substrate solution (# T0440, Sigma-Aldrich), block the light, leave at room temperature for 3 minutes, and stop by adding 50 ul 2.5M sulfuric acid (# S1478, Samchun) to stop the reaction.
- ® Discover System Promega was used to measure absorbance at 450 nm. The result is shown in FIG.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 according to the present invention binds to PD-L1 with high affinity, while inhibiting the formation of PD-1 / PD-L1 complex, thereby preventing PD-1 / PD-L1 mediated T. T cell depletion that avoids cellular activity can be suppressed.
- the antibody or antigen-binding fragment thereof that binds to PD-L1 according to the present invention can be usefully used for the prevention or treatment of the desired cancer or infectious disease.
Abstract
Description
Claims (12)
- 서열번호 1 내지 서열번호 7로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 중쇄 CDR1, A heavy chain CDR1 comprising a sequence having 90% or more sequence homology with a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 7,서열번호 8 내지 서열번호 15로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 중쇄 CDR2, 및 A heavy chain CDR2 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 8 to 15, and서열번호 16 내지 서열번호 25로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 중쇄 CDR3를 포함하는 중쇄 가변영역, 및 A heavy chain variable region comprising a heavy chain CDR3 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 16 to 25, and서열번호 88 내지 서열번호 102로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 경쇄 CDR1, Light chain CDR1 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 88 to 102,서열번호 103 내지 서열번호 119로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 경쇄 CDR2, 및A light chain CDR2 comprising a sequence having 90% or more sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 103 through 119, and서열번호 120 내지 서열번호 144로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 경쇄 CDR3을 포함하는 경쇄 가변영역을 포함하는, PD-L1에 결합하는 항체 또는 이의 항원 결합단편.An antibody binding to PD-L1 or an antigen binding thereof, comprising a light chain variable region comprising a light chain CDR3 comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 120 to 144 snippet.
- 제1항에 있어서, The method of claim 1,서열번호 1의 중쇄 CDR1, 서열번호 8의 중쇄 CDR2, 및 서열번호 16의 중쇄 CDR3을 포함하는 중쇄 가변영역, A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 8, and a heavy chain CDR3 of SEQ ID NO: 16,서열번호 2의 중쇄 CDR1, 서열번호 9의 중쇄 CDR2, 및 서열번호 17의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17,서열번호 2의 중쇄 CDR1, 서열번호 9의 중쇄 CDR2, 및 서열번호 18의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 18,서열번호 3의 중쇄 CDR1, 서열번호 10의 중쇄 CDR2, 및 서열번호 19의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 10, and a heavy chain CDR3 of SEQ ID NO: 19,서열번호 4의 중쇄 CDR1, 서열번호 11의 중쇄 CDR2, 및 서열번호 20의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 11, and a heavy chain CDR3 of SEQ ID NO: 20,서열번호 5의 중쇄 CDR1, 서열번호 12의 중쇄 CDR2, 및 서열번호 21의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 21,서열번호 6의 중쇄 CDR1, 서열번호 13의 중쇄 CDR2, 및 서열번호 22의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 6, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 22,서열번호 2의 중쇄 CDR1, 서열번호 9의 중쇄 CDR2, 및 서열번호 23의 중쇄 CDR3을 포함하는 중쇄 가변영역,A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 23,서열번호 7의 중쇄 CDR1, 서열번호 14의 중쇄 CDR2, 및 서열번호 24의 중쇄 CDR3을 포함하는 중쇄 가변영역, A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 24,서열번호 2의 중쇄 CDR1, 서열번호 15의 중쇄 CDR2, 및 서열번호 25의 중쇄 CDR3을 포함하는 중쇄 가변영역, 또는A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 15, and a heavy chain CDR3 of SEQ ID NO: 25, or서열번호 2의 중쇄 CDR1, 서열번호 9의 중쇄 CDR2, 및 서열번호 17의 중쇄 CDR3을 포함하는 중쇄 가변영역을 포함하는 항체 또는 이의 항원 결합단편.An antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 17.
- 제1항에 있어서, The method of claim 1,서열번호 88의 경쇄 CDR1, 서열번호 103의 경쇄 CDR2, 및 서열번호 120의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 88, a light chain CDR2 of SEQ ID NO: 103, and a light chain CDR3 of SEQ ID NO: 120,서열번호 89의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 121의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 121,서열번호 90의 경쇄 CDR1, 서열번호 105의 경쇄 CDR2, 및 서열번호 122의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 90, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 122,서열번호 91의 경쇄 CDR1, 서열번호 106의 경쇄 CDR2, 및 서열번호 123의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising the light chain CDR1 of SEQ ID NO: 91, the light chain CDR2 of SEQ ID NO: 106, and the light chain CDR3 of SEQ ID NO: 123,서열번호 89의 경쇄 CDR1, 서열번호 107의 경쇄 CDR2, 및 서열번호 124의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 107, and a light chain CDR3 of SEQ ID NO: 124,서열번호 92의 경쇄 CDR1, 서열번호 108의 경쇄 CDR2, 및 서열번호 122의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 92, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 122,서열번호 93의 경쇄 CDR1, 서열번호 109의 경쇄 CDR2, 및 서열번호 125의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising the light chain CDR1 of SEQ ID NO: 93, the light chain CDR2 of SEQ ID NO: 109, and the light chain CDR3 of SEQ ID NO: 125,서열번호 94의 경쇄 CDR1, 서열번호 110의 경쇄 CDR2, 및 서열번호 126의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 94, a light chain CDR2 of SEQ ID NO: 110, and a light chain CDR3 of SEQ ID NO: 126,서열번호 95의 경쇄 CDR1, 서열번호 111의 경쇄 CDR2, 및 서열번호 127의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 95, a light chain CDR2 of SEQ ID NO: 111, and a light chain CDR3 of SEQ ID NO: 127,서열번호 96의 경쇄 CDR1, 서열번호 112의 경쇄 CDR2, 및 서열번호 128의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 96, a light chain CDR2 of SEQ ID NO: 112, and a light chain CDR3 of SEQ ID NO: 128,서열번호 89의 경쇄 CDR1, 서열번호 108의 경쇄 CDR2, 및 서열번호 129의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 129,서열번호 89의 경쇄 CDR1, 서열번호 105의 경쇄 CDR2, 및 서열번호 130의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 130,서열번호 89의 경쇄 CDR1, 서열번호 113의 경쇄 CDR2, 및 서열번호 131의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 113, and a light chain CDR3 of SEQ ID NO: 131,서열번호 97의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 132의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 97, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 132,서열번호 89의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 133의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 133,서열번호 97의 경쇄 CDR1, 서열번호 114의 경쇄 CDR2, 및 서열번호 134의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, light chain CDR2 of SEQ ID NO: 114, and light chain CDR3 of SEQ ID NO: 134,서열번호 92의 경쇄 CDR1, 서열번호 115의 경쇄 CDR2, 및 서열번호 135의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 92, a light chain CDR2 of SEQ ID NO: 115, and a light chain CDR3 of SEQ ID NO: 135,서열번호 98의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 130의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 98, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 130,서열번호 89의 경쇄 CDR1, 서열번호 116의 경쇄 CDR2, 및 서열번호 121의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 116, and the light chain CDR3 of SEQ ID NO: 121,서열번호 89의 경쇄 CDR1, 서열번호 108의 경쇄 CDR2, 및 서열번호 136의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 136,서열번호 99의 경쇄 CDR1, 서열번호 105의 경쇄 CDR2, 및 서열번호 137의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 99, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 137,서열번호 89의 경쇄 CDR1, 서열번호 117의 경쇄 CDR2, 및 서열번호 138의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 117, and a light chain CDR3 of SEQ ID NO: 138,서열번호 89의 경쇄 CDR1, 서열번호 118의 경쇄 CDR2, 및 서열번호 133의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 118, and a light chain CDR3 of SEQ ID NO: 133,서열번호 89의 경쇄 CDR1, 서열번호 119의 경쇄 CDR2, 및 서열번호 139의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 119, and a light chain CDR3 of SEQ ID NO: 139,서열번호 100의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 140의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 100, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 140,서열번호 89의 경쇄 CDR1, 서열번호 108의 경쇄 CDR2, 및 서열번호 141의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 108, and a light chain CDR3 of SEQ ID NO: 141,서열번호 89의 경쇄 CDR1, 서열번호 105의 경쇄 CDR2, 및 서열번호 139의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 139,서열번호 89의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 142의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 142,서열번호 89의 경쇄 CDR1, 서열번호 105의 경쇄 CDR2, 및 서열번호 143의 경쇄 CDR3를 포함하는 경쇄 가변영역, A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 89, a light chain CDR2 of SEQ ID NO: 105, and a light chain CDR3 of SEQ ID NO: 143,서열번호 101의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 141의 경쇄 CDR3를 포함하는 경쇄 가변영역, 또는A light chain variable region comprising the light chain CDR1 of SEQ ID NO: 101, the light chain CDR2 of SEQ ID NO: 104, and the light chain CDR3 of SEQ ID NO: 141, or서열번호 102의 경쇄 CDR1, 서열번호 104의 경쇄 CDR2, 및 서열번호 144의 경쇄 CDR3를 포함하는 경쇄 가변영역을 포함하는 항체 또는 이의 항원 결합단편.An antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 102, a light chain CDR2 of SEQ ID NO: 104, and a light chain CDR3 of SEQ ID NO: 144.
- 제1항에 있어서, 서열번호 26 내지 서열번호 34로 구성된 군에서 선택되는 중쇄 가변영역 FR1, The method according to claim 1, wherein heavy chain variable region FR1 selected from the group consisting of SEQ ID NO: 26 to SEQ ID NO: 34,서열번호 35 내지 서열번호 41로 구성된 군에서 선택되는 중쇄 가변영역 FR2, A heavy chain variable region FR2 selected from the group consisting of SEQ ID NOs: 35 to 41;서열번호 42 내지 서열번호 49로 구성된 군에서 선택되는 중쇄 가변영역 FR3, 또는 A heavy chain variable region FR3 selected from the group consisting of SEQ ID NOs: 42 to 49, or서열번호 50 내지 서열번호 54로 구성된 군에서 선택되는 중쇄 가변영역 FR4를 포함하는 항체 또는 이의 항원 결합단편.An antibody or antigen-binding fragment thereof comprising a heavy chain variable region FR4 selected from the group consisting of SEQ ID NO: 50 to SEQ ID NO: 54.
- 제1항에 있어서, 서열번호 145 내지 서열번호 163로 구성된 군에서 선택되는 경쇄 가변영역 FR1, According to claim 1, Light chain variable region FR1 selected from the group consisting of SEQ ID NO: 145 to SEQ ID NO: 163,서열번호 164 내지 서열번호 184로 구성된 군에서 선택되는 경쇄 가변영역 FR2, Light chain variable region FR2 selected from the group consisting of SEQ ID NOs: 164 to 184,서열번호 185 내지 서열번호 210로 구성된 군에서 선택되는 경쇄 가변영역 FR3, 또는 Light chain variable region FR3 selected from the group consisting of SEQ ID NOs: 185 to 210, or서열번호 211 내지 서열번호 216로 구성된 군에서 선택되는 경쇄 가변영역 FR4를 포함하는 항체 또는 이의 항원 결합단편.An antibody or antigen-binding fragment thereof comprising a light chain variable region FR4 selected from the group consisting of SEQ ID NOs: 211 to 216.
- 제1항에 있어서, 서열번호 57 내지 서열번호 87로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 중쇄 가변영역을 포함하는 항체 또는 이의 항원 결합단편.The antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NO: 57 to SEQ ID NO: 87.
- 제1항에 있어서, 서열번호 217 내지 서열번호 247로 구성된 군에서 선택되는 서열과 90% 이상의 서열 상동성을 가지는 서열을 포함하는 경쇄 가변영역을 포함하는 항체 또는 이의 항원 결합단편.The antibody or antigen-binding fragment thereof according to claim 1, comprising a light chain variable region comprising a sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NOs: 217 to 247.
- 제 1 항 내지 제 7 항 중 어느 한 항의 항체 또는 이의 항원 결합단편을 코딩하는 핵산.A nucleic acid encoding the antibody of claim 1 or an antigen binding fragment thereof.
- 제8항의 핵산을 포함하는 발현벡터.An expression vector comprising the nucleic acid of claim 8.
- 제9항의 발현 벡터로 형질전환된 세포.A cell transformed with the expression vector of claim 9.
- 다음 단계를 포함하는 PD-L1에 결합하는 항체 또는 그의 항원 결합 단편의 제조방법:Method for producing an antibody or antigen-binding fragment thereof that binds to PD-L1, comprising the following steps:(a) 제10항의 세포를 배양하는 단계; 및(a) culturing the cells of claim 10; And(b) 상기 배양된 세포에서 항체 또는 그의 항원 결합 단편을 회수하는 단계.(b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.
- 제 1 항 내지 제 7 항 중 어느 한 항의 항체 또는 그의 항원 결합 단편을 유효성분으로 포함하는 암 또는 감염 질환의 예방 또는 치료용 조성물.A composition for preventing or treating cancer or infectious disease comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 7 as an active ingredient.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019105664A RU2721582C1 (en) | 2016-08-05 | 2017-08-07 | Antibodies against ligand-1 programmed death (pd-l1) and application thereof |
US16/321,412 US10919966B2 (en) | 2016-08-05 | 2017-08-07 | Antibody to programmed death-ligand 1 (PD-L1) and use thereof |
CA3032806A CA3032806C (en) | 2016-08-05 | 2017-08-07 | Antibody to programmed death-ligand 1 (pd-l1) and use thereof |
AU2017306507A AU2017306507B2 (en) | 2016-08-05 | 2017-08-07 | Antibody to programmed death-ligand 1 (PD-L1) and use thereof |
CN201780055412.7A CN110072889B (en) | 2016-08-05 | 2017-08-07 | Antibodies against programmed cell death ligand 1 (PD-L1) and uses thereof |
BR112019002282A BR112019002282A2 (en) | 2016-08-05 | 2017-08-07 | pd-11 binding antibody or antibody antigen-binding fragment, method for producing the same and composition for the prevention or treatment of cancer or infectious diseases |
JP2019528010A JP6925421B2 (en) | 2016-08-05 | 2017-08-07 | Antibodies to programmed cell death protein ligand-1 (PD-L1) and their uses |
EP17837300.7A EP3495391A4 (en) | 2016-08-05 | 2017-08-07 | Antibody against programmed death-ligand 1 (pd-l1), and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160100211 | 2016-08-05 | ||
KR10-2016-0100211 | 2016-08-05 | ||
KR10-2017-0099673 | 2017-08-07 | ||
KR1020170099673A KR102048477B1 (en) | 2016-08-05 | 2017-08-07 | Antibodies Against Programmed death-ligand 1 and Uses Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018026249A1 true WO2018026249A1 (en) | 2018-02-08 |
Family
ID=61073160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/008495 WO2018026249A1 (en) | 2016-08-05 | 2017-08-07 | Antibody against programmed death-ligand 1 (pd-l1), and use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018026249A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021517904A (en) * | 2018-04-10 | 2021-07-29 | ワイ−バイオロジクス・インコーポレイテッド | Cell Engagement Binding Molecules |
WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988006630A1 (en) | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
WO1988007085A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Process for the purification of recombinant polypeptides |
WO1988007086A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US20090055944A1 (en) * | 2005-07-01 | 2009-02-26 | Medarex, Inc. | Human monoclonal antibodies to be programmed death ligand 1 (pd-l1) |
WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2015061668A1 (en) * | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
-
2017
- 2017-08-07 WO PCT/KR2017/008495 patent/WO2018026249A1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988006630A1 (en) | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
WO1988007085A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Process for the purification of recombinant polypeptides |
WO1988007086A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US20090055944A1 (en) * | 2005-07-01 | 2009-02-26 | Medarex, Inc. | Human monoclonal antibodies to be programmed death ligand 1 (pd-l1) |
US20110209230A1 (en) * | 2005-07-01 | 2011-08-25 | Korman Alan J | Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1) |
WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2015061668A1 (en) * | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021517904A (en) * | 2018-04-10 | 2021-07-29 | ワイ−バイオロジクス・インコーポレイテッド | Cell Engagement Binding Molecules |
JP7076571B2 (en) | 2018-04-10 | 2022-05-27 | ワイ-バイオロジクス・インコーポレイテッド | Cell engagement binding molecule |
WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015058573A1 (en) | Monoclonal antibody for antagonizing and inhibiting binding of programmed death (pd-1) to ligand thereof and coding sequence and use thereof | |
WO2018026248A1 (en) | Novel antibody against programmed cell death protein (pd-1), and use thereof | |
WO2020251187A1 (en) | Antibody to tigit and use thereof | |
WO2014090053A1 (en) | Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial cell growth factor and its receptor, and coding sequence and use thereof | |
WO2022039490A1 (en) | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof | |
WO2016137108A1 (en) | Novel antibody binding to tfpi and composition comprising the same | |
WO2019112347A2 (en) | Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof | |
WO2014077648A1 (en) | Antibody binding specifically to human and mouse l1cam protein, and use therefor | |
WO2019050362A2 (en) | Antibody against human dlk1 and use thereof | |
WO2020080908A1 (en) | Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same | |
WO2021020846A1 (en) | Anti-her2/anti-4-1bb bispecific antibody and use thereof | |
WO2010047509A9 (en) | Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same | |
WO2018026249A1 (en) | Antibody against programmed death-ligand 1 (pd-l1), and use thereof | |
WO2019125070A1 (en) | Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof | |
WO2019078699A2 (en) | Anti-vista antibody and use thereof | |
WO2021101346A1 (en) | Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof | |
WO2021020845A1 (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
WO2022035201A1 (en) | Fusion protein comprising il-12 and anti-fap antibody, and use thereof | |
WO2022149837A1 (en) | Anti-fgfr3 antibody and use thereof | |
WO2022177394A1 (en) | Bispecific single domain antibody to pd-l1 and cd47 and use thereof | |
WO2022124866A1 (en) | Anti-pd-1 antibody and uses thereof | |
WO2022085905A1 (en) | Antibody binding specifically to sars-cov-2 spike protein and use thereof | |
WO2021101349A1 (en) | Antibody that binds to ror1 and b7-h3, antibody-drug conjugate containing same, and use thereof | |
WO2020204305A1 (en) | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
WO2015088256A1 (en) | Binding molecules capable of neutralizing rabies viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17837300 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3032806 Country of ref document: CA Ref document number: 2019528010 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019002282 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017837300 Country of ref document: EP Effective date: 20190305 |
|
ENP | Entry into the national phase |
Ref document number: 2017306507 Country of ref document: AU Date of ref document: 20170807 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112019002282 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190204 |